Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction

Georg Griesinger, Herman Tournaye, Nick Macklon, Felice Petraglia, Petra Arck, Christophe Blockeel, Peter van Amsterdam, Claire Pexman-Fieth, Bart Cjm Fauser

Research output: Contribution to journalScientific reviewpeer-review

45 Citations (Scopus)


The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.

Original languageEnglish
Pages (from-to)249-259
Number of pages11
JournalReproductive BioMedicine Online
Issue number2
Publication statusPublished - Feb 2019

Bibliographical note

Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.


  • Duphaston
  • Dydrogesterone
  • In-vitro fertilization
  • Luteal phase support
  • Pharmacological profile
  • Progesterone


Dive into the research topics of 'Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction'. Together they form a unique fingerprint.

Cite this